Postherpetic neuralgia (PHN) data and efficacy data at four years

By helping prevent shingles, SHINGRIX significantly decreased the incidence of PHN in patients aged ≥70 overall1*

Table with efficacy data for postherpetic neuralgia from the ZOE-50 and ZOE-70 clinical trials Table with efficacy data for postherpetic neuralgia from the ZOE-50 and ZOE-70 clinical trials

Adapted from SHINGRIX Product Monograph.

8,250 PATIENTS ≥70 YEARS OF AGE RECEIVED SHINGRIX.¹

Four CASES OF PHN WERE REPORTED IN THIS AGE GROUP.1

The benefit of SHINGRIX on PHN can be attributed to the effect of the vaccine on the prevention of HZ. A further reduction of PHN incidence in subjects with confirmed HZ could not be demonstrated due to the limited number of HZ cases in the vaccine group.¹

SHINGRIX is not indicated for the treatment of HZ or PHN.1

* PHN was defined as shingles-associated pain rated as ≥3 on a 0–10 scale, occurring or persisting for at least 90 days following the onset of rash using the Zoster Brief Pain Inventory questionnaire.1,2

Efficacy remained high four years post-vaccination in adults ≥70 years old1,2

The duration of protection beyond four years is currently under investigation.

Efficacy 4 years post-vaccination (ZOE-50 and ZOE-70 pooled data) graph Efficacy 4 years post-vaccination (ZOE-50 and ZOE-70 pooled data) graph

Based on pooled data from ZOE-50 and ZOE-70.

Efficacy remained high four years post-vaccination in adults ≥50 years old1

Cumulative incidence of herpes zoster over time in adults aged ≥50 in the ZOE-50 study (mTVC)1

The duration of protection beyond four years is currently under investigation.

 Efficacy 4 years post-vaccination (ZOE-50 data) graph  Efficacy 4 years post-vaccination (ZOE-50 data) graph

Adapted from SHINGRIX Product Monograph.

In the fourth year after vaccination, vaccine efficacy (VE) against shingles in patients ≥50 years in ZOE-50 was 93.1% vs. placebo (95% CI: 81.2, 98.2).1

 

References

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., June 3, 2020.
  2. Cunningham AL et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375(11):1019-1032.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
  4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK Group of Companies or its licensor.

PM-CA-SGX-WCNT-210001 | November 2021